Compare Google Inc (GOOG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Twist Bioscience Corp — how do they compare? Google Inc trades at $349.59 (market cap $4.24T), while Twist Bioscience Corp trades at $161.11 (market cap $10.08B). The key difference: Google Inc is far larger — about 420.6× Twist Bioscience Corp's market cap, and Google Inc pays a 0.26% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Twist Bioscience Corp for 27 Days on average.
| GOOG | TWST | |
|---|---|---|
Market Cap | $4.24T | $10.08B |
Volume | 13,937,902 | 4,229,037 |
Sector | Media | Health |
52-Week High | $399.06 | $205.00 |
52-Week Low | $237.49 | $25.45 |
Typical Hold Time | 137 Days | 27 Days |
Enterprise Value | $4.13T | $10.01B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.
Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
